Frontier Diagnostics

Who are Frontier Diagnostics

Frontier Diagnostics are improving the survival rates of cancer patients and increasing their quality of life by using new revolutionary early detection techniques, Ai-driven tools, genomic insights, and precision medicine.

Investment Highlights

✔ HMRC EIS Approved with 30% Income Tax Relief 

✔ 10.3x Target returns including EIS Tax Relief 

✔ A management team with unmatched levels of expertise in key fields. 

✔ £24.8m Conservative Growth Profit Forecast - 2029. 

✔ The global breast cancer diagnostics market alone is expected to reach over USD 9.00 billion by 2033. That’s a CAGR of 7.2% 

✔ 1 in 8 women will develop breast cancer in their lifetime. *

‘By quantifying circulating tumour cells (CTCs), we can identify early tumour activity in patients. The quantification of CTCs allows us to predict the effectiveness of a chemotherapeutic agent in percentage terms before it is even administered. That means we know how many cells will be killed in each round of therapy. We are developing a new platform-based solution to CTC cell counting for routine medical diagnostics’
Dr. Martin Burrow CEO, The former Head of Asia Pacific for Thermo Fisher

* https://amp.cancer.org 

Any person accessing the email or profile and considering potential investment opportunities featured on the email should make their own commercial assessment of an investment opportunity after seeking the advice of an appropriately authorised or regulated financial advisor. This email should not be construed as advice or a personal recommendation to any prospective investor.